REFERENCES
- Addison C L, Daniel O T, Burdick M D, Liu H, Ehlert J E, Xue Y Y, Buechi L, Walz A, Richmond A, Strieter R M. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000; 165: 5269–5277, [PUBMED], [INFOTRIEVE], [CSA]
- Appleton I, Tomlinson A, Colville-Nash P R, Willoughby D A. Temporal and spatial immuno-localisation of cytokines in murine chronic granulomatous tissue. Lab Invest 1993; 69: 405–414, [PUBMED], [INFOTRIEVE], [CSA]
- Appleton I, Brown N J, Willis D, Colville-Nash P R, Alam C, Brown J R, Willoughby D A. The role of vascular endothelial growth factor in a murine chronic granulomatous tissue air pouch model of angiogenesis. J Pathol 1996; 180: 90–94, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev 2002; 13: 135–141, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Barcelos L S, Talvani A, Teixeira A S, Cassali G D, Andrade S P, Teixeira M M. Production and in vivo effects of chemokines CXCL1-3/KC and CCL2/JE in a model of inflammatory angiogenesis in mice. Inflammation Res 2004; 53: 534–539, [CSA], [CROSSREF]
- Belo A V, Barcelos L S, Teixeira M M, Ferreira M AND, Andrade S P. Differential effects of antiangiogenic compounds in neovascularization, leukocyte recruitment, VEGF production, and tumor growth in mice. Cancer Invest 2004; 22: 723–729, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Belperio J A, Keane M P, Arenberg D A, Addison C L, Ehlert J E, Burdick M D, Strieter R M. CXC chemokines in angiogenesis. J Leukoc Biol 2000; 68: 1–8, [PUBMED], [INFOTRIEVE], [CSA]
- Benzaquen L R, Brugnara C, Byers H R, Gattom-Celli S, Halperin J A. Clotrimazole inhibits cell proliferation invitro and in vivo. Nat Med 1995; 1: 534–540, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Calabrese L, Fleischer A B. Thalidomide: current and potential clinical applications. Am J Med 2000; 108: 487–495, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Chavakis T, Cines B D, Rhee J.-S., Liang D O, Schubert U, Hammes H.-P., Higazi A AR, Nawroth P P, Preissner K T, Bdeir K. Regulation of neovascularization by human neutrophil peptides (α -defensins): a link between inflammation and angiogenesis. FASEB J 2004; 18: 1306–1308, [PUBMED], [INFOTRIEVE], [CSA]
- Chen H X, Gore-Langton R E, Cheson B D. Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Huntingt) 2001; 15: 1017, 1020, 1023–1026, [CSA]
- D'Amato R J, Loughnan M S, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–4085, [PUBMED], [INFOTRIEVE], [CSA]
- Dvorak H F. Vascular permeability factor/ Vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 21: 4368–4380, [CSA], [CROSSREF]
- Fajardo L F, Kwan H H, Kowalski J, Prionas S D, Allison A C. Dual role of tumor necrosis factor-α in angiogenesis. Am J Pathol 1992; 140: 539–544, [PUBMED], [INFOTRIEVE], [CSA]
- Ferreira M AND, Barcelos L S, Campos P P, Vasconcelos A C, Teixeira M M, Andrade S P. Sponge-induced angiogenesis and inflammation in PAF receptor-deficient mice (PAFR-KO). Br J Pharmacol 2004; 141: 1185–1192, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995; 1: 27–31, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Griffioen A, Molema G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000; 52: 237–268, [PUBMED], [INFOTRIEVE], [CSA]
- Hu D E, Fan T P. Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor lavendustin A. Br J Pharmacol 1995; 114: 262–268, [PUBMED], [INFOTRIEVE], [CSA]
- Hu D E, Hory Y, Presta M, Gresham G A, Fan T P. Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies. Inflammation 1994; 18: 45–48, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hunt T K, Knighton D R, Thakral K K, Goodson W HIII, Andrews W S. Studies on inflammation and wound healing: angiogenesis and collagen synthesis stimulated in vivo by resident and activated wound macrophages. Surgery 1984; 96: 48–54, [PUBMED], [INFOTRIEVE], [CSA]
- Jackson J R, Seed M P, Kircher C H, Willoughby D A, Winkler J D. The codependence of angiogenesis and chronic inflammation. FASEB J 1997; 11: 457–465, [PUBMED], [INFOTRIEVE], [CSA]
- Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999; 169: 175–194, [PUBMED], [INFOTRIEVE], [CSA]
- Kruse F E, Joussen K, Rohrschneider K, Becker M B, Volicicker H E. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe's Arch Clin Exp Opthalmol 1998; 236: 461–466, [CSA], [CROSSREF]
- Liehn E A, Schober A, Weber C. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 1891–1896, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Machado R DP, Santos R AS, Andrade S P. Mechanisms of angiotensin-(1-7)-induced inhibition of angiogenesis. Am J Physiol Reg Integ Comp Physiol 2001; 280: R994–R1000, [CSA]
- Marx N, Schonbeck U, Lazar M A, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097–1103, [PUBMED], [INFOTRIEVE], [CSA]
- Matsushima K, Larsen C G, DuBois G C, Oppenheim J J. Purification and characterization of a novel monocyte chemotatic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989; 169: 1485–1491, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov Today 2001; 6: 1005–1024, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M. Neutrophil-activating properties of the melanoma growth-stimulatory activity. J Exp Med 1990; 171: 1797–1802, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ohta M Y, Nagai Y, Takamura T, Nohara E, Kobayashi K. Inhibitory effect of troglitazone on TNF-α -induced expression of monocyte chemoattractant protein-1 (MCP-1) in human endothelial cells. Diabetes Res Clin Pract 2000; 48: 171–176, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Saltiel A R, Olefsky J M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661–1669, [PUBMED], [INFOTRIEVE], [CSA]
- Sampaio E P, Sarno E N, Galilly R, Cohn Z A, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699–703, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sheskin J. Thalidomide in the treatment of lepra reaction. Clin Pharmacol Ther 1965; 6: 303–306, [CSA]
- Xin X, Yang S, Kowalski J, Gerritsen M E. Peroxisome proliferator-activated receptor-γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol. Chem 1999; 274: 9116–9121, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]